← All trials
NCT07052201
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Jan 31, 2028
- Completion date
- May 31, 2028
- First posted
- Jul 4, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 970
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversitySponsor investigator
- Chongqing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.